Search

Your search keyword '"Pinazo, Maria-Jesus"' showing total 169 results
Start Over Author "Pinazo, Maria-Jesus" Publication Year Range Last 50 years
169 results on '"Pinazo, Maria-Jesus"'

1. Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial

Author

Pinazo, Maria-Jesus, Forsyth, Colin, Losada, Irene, Esteban, Elena Trigo, García-Rodríguez, Magdalena, Villegas, Maria Luz, Molina, Israel, Crespillo-Andújar, Clara, Gállego, Montserrat, Ballart, Cristina, Ramirez, Juan Carlos, Aden, Tilman, Hoerauf, Achim, Pfarr, Kenneth, Vaillant, Michel, Marques, Tayná, Fernandes, Jayme, Blum, Bethania, Ribeiro, Isabela, Sosa-Estani, Sergio, Barreira, Fabiana, and Gascón, Joaquim

Published
2024
Full Text
View/download PDF

2. Evaluation of the accuracy of a multi-infection screening test based on a multiplex immunoassay targeting imported diseases common in migrant populations

Author

Aguilar, Ruth, Cruz, Angeline, Jiménez, Alfons, Almuedo, Alex, Saumell, Carme Roca, Lopez, Marina Gigante, Gasch, Oriol, Falcó, Gemma, Jiménez-Lozano, Ana, Martínez-Perez, Angela, Sanchez-Collado, Consol, Tedesco, Andrea, López, Manuel Carlos, Pinazo, María Jesús, Leonel, Thais, Bisoffi, Zeno, Färnert, Anna, Dobaño, Carlota, and Requena-Méndez, Ana

Published
2024
Full Text
View/download PDF

5. Self-Evaluating Participatory Research Projects: A Content Validation of the InSPIRES Online Impact Evaluation Tool

Author

Gignac, Florence, Gresle, Anne-Sophie, Santoro Lamelas, Valeria, Yepes-Baldó, Montserrat, de la Torre, Leonardo, and Pinazo, Maria-Jesus

Abstract

Research projects involving science shops and citizen science in their promotion of participatory approaches are flourishing globally. However, an instrument evaluating the impacts of such approaches at different stages of a participatory research processes has yet to be validated. The InSPIRES H2020 project developed an impact evaluation tool for just this purpose, consisting of 64 items that reflect upon the dimensions of "knowledge democracy," "citizen-led research," "participatory dynamics," "transformative change," and "integrity." In this article, we seek to test the content validity of this tool and to provide recommendations that can ensure its validity. A panel of nine experts was created to evaluate each item as regards the following three criteria: representativeness, relevance, and clarity. The Aiken's V and Wilson Score methods were used to assess the tool's content validity based on the experts' ratings. Experts' written comments were also reviewed. At the panel level, 75% of the items were considered satisfactory in relation to each of the three validity criteria. However, at the population level, 72% of the items suggested that parts of the tool were not valid and required revision. The main suggestions from the experts pointed to the need to reformulate items in which the separation between science and society appeared reinforced and to develop more items about the gender perspective of a research project. The revised version of the tool should serve as a well-founded, comprehensive evaluation instrument for on-going and future projects whose goal is to self-reflect and compare participatory research processes.

Published
2021
Full Text
View/download PDF

7. A Smartphone App for Real-Time Assessment of Malaria Prophylaxis Adverse Events.

Author

Rodriguez-Valero, Natalia, Ledesma-Carbayo, Maria Jesus, Martí-Soler, Helena, Cuadrado Sanchez, Daniel, Vladimirov, Alexander, Camprubí-Ferrer, Daniel, Pinazo, Maria Jesus, Losada, Irene, Almuedo-Riera, Alex, Romero, Lucia, Roman, Anna, Vera, Isabel, Roldan-Torralvo, Montserrat, Ferrer, Elisabeth, de Alba, Teresa, Jimenez, Alejandra, Gómez-Valverde, Juan Jose, Muñoz, Jose, and Luengo Oroz, Miguel

Subjects
MOBILE apps, MALARIA, PREVENTIVE medicine, ELECTRONIC surveillance, INTERNATIONAL travel
Abstract

Background:Growth of international travel to malarial areas over the last decades has contributed to more travelers taking malaria prophylaxis. Travel-related symptoms may be wrongly attributed to malaria prophylaxis and hinder compliance. Here, we aimed to assess the frequency of real-time reporting of symptoms by travelers following malaria prophylaxis using a smartphone app. Method:Adult international travelers included in this single-center study (Barcelona, Spain) used the smartphone Trip Doctor® app developed by our group for real-time tracking of symptoms and adherence to prophylaxis. Results:Six hundred four (n = 604) international travelers were included in the study; 74.3% (449) used the app daily, and for one-quarter of travelers, malaria prophylaxis was prescribed. Participants from the prophylaxis group traveled more to Africa (86.7% vs. 4.3%; p < 0.01) and to high travel medical risk countries (60.8% vs. 18%; p < 0.01) and reported more immunosuppression (30.8% vs. 23.1% p < 0.01). Regarding symptoms, no significant intergroup differences were observed, and no relationship was found between the total number of malarial pills taken and reported symptoms. Conclusions:In our cohort, the number of symptoms due to malaria prophylaxis was not significantly higher than in participants for whom prophylaxis was not prescribed, and the overall proportion of symptoms is higher compared with other studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial

Author

Arteaga, Roger, de la Barra, Anabelle, Camacho Borja, Jhonny, Martinez, Ivana, Fernandes, Jayme, Garcia, Lineth, Lozano, Daniel, Palacios, Alejandro, Schijman, Alejandro, Pinazo, Maria Jesus, Pinto, Jimmy, Rojas, Gimena, Estevao, Igor, Ortega-Rodriguez, Uriel, Mendes, Maria Tays, Schuck, Edgar, Hata, Katsura, Maki, Noritsugu, Asada, Makoto, Torrico, Faustino, Gascón, Joaquim, Barreira, Fabiana, Blum, Bethania, Almeida, Igor C, Alonso-Vega, Cristina, Barboza, Tayná, Bilbe, Graeme, Correia, Erika, Garcia, Wilson, Ortiz, Lourdes, Parrado, Rudy, Ramirez, Juan Carlos, Ribeiro, Isabela, Strub-Wourgaft, Nathalie, Vaillant, Michel, and Sosa-Estani, Sergio

Published
2021
Full Text
View/download PDF

9. Clinical use of molecular methods for Trypanosoma cruzi infection in endemic and non-endemic countries: Benefits, limitations and challenges

Author

Pinazo, Maria-Jesus, primary, Forsyth, Colin J., additional, Lopez-Albizu, Constanza, additional, Bisio, Margarita María Catalina, additional, González-Martínez, Adriana, additional, Bohorquez, Laura, additional, Pinto, Jimy, additional, Molina, Israel, additional, Marchiol, Andrea, additional, Herazo, Rafael, additional, Galván, Irene Losada, additional, Marques, Tayná, additional, Barreira, Fabiana, additional, Villar, Juan Carlos, additional, Sguassero, Yanina, additional, Santini, Maria Soledad, additional, Altcheh, Jaime, additional, Alarcón de Noya, Belkisyolé, additional, and Sosa-Estani, Sergio, additional

Published
2023
Full Text
View/download PDF

10. Chagas Disease in Europe

Author

Alonso-Padilla, Julio, Pinazo, María Jesús, Gascón, Joaquim, Kaufmann, Stefan H.E., Section Editor, Weber, Olaf, Series Editor, Altcheh, Jaime Marcelo, editor, and Freilij, Hector, editor

Published
2019
Full Text
View/download PDF

11. An Innovative Online Tool to Self-evaluate and Compare Participatory Research Projects Labelled as Science Shops or Citizen Science

Author

on behalf of the InSPIRES Consortium, Gresle, Anne-Sophie, Cigarini, Anna, de la Torre Avila, Leonardo, Jimeno, Irene, Bagnoli, Franco, Dempere, Herman, Ribera, Mireia, Puertas, Eloi, Perelló, Josep, Pinazo, María Jesús, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Woeginger, Gerhard, Editorial Board Member, Yung, Moti, Editorial Board Member, El Yacoubi, Samira, editor, Bagnoli, Franco, editor, and Pacini, Giovanna, editor

Published
2019
Full Text
View/download PDF

14. Plasma-Derived Extracellular Vesicles as Potential Biomarkers in Heart Transplant Patient with Chronic Chagas Disease

Author

Cortes-Serra, Nuria, Mendes, Maria Tays, Mazagatos, Clara, Segui-Barber, Joan, Ellis, Cameron C., Ballart, Cristina, Garcia-Alvarez, Ana, Gallego, Montserrat, Gascon, Joaquim, Almeida, Igor C., Pinazo, Maria Jesus, and Fernandez-Becerra, Carmen

Subjects
Posaconazole -- Health aspects, Heart transplantation -- Health aspects, Parasitic diseases -- Health aspects, Epidemiology -- Health aspects, Cardiac patients -- Health aspects, Chagas disease -- Health aspects, Biological markers -- Health aspects, Health
Abstract

Chagas disease, caused by Trypanosoma cruzi parasite, is one of the most prevalent parasitic infections in Latin America and is responsible for millions of clinical cases. However, mainly because of [...]

Published
2020
Full Text
View/download PDF

17. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial

Author

Santina, Glaucia, Blum, Bethania, Correia, Erika, Garcia-Bournisen, Facundo, Vaillant, Michel, Morales, Jimena Ramos, Pinto Rocha, Jimy Jose, Rojas Delgadillo, Gimena, Magne Anzoleaga, Helmut Ramon, Mendoza, Nilce, Quechover, Roxana Challapa, Caballero, Maria Yurly Escobar, Lozano Beltran, Daniel Franz, Zalabar, Albert Mendoza, Rojas Panozo, Lizeth, Palacios Lopez, Alejandro, Torrico Terceros, Dunia, Fernandez Galvez, Violeta Alejandra, Cardozo, Letty, Cuellar, Gabriela, Vasco Arenas, Rudy Nelson, Gonzales, Isabel, Hoyos Delfin, Carlos Florencio, Garcia, Lineth, Parrado, Rudy, de la Barra, Anabelle, Montano, Nair, Villarroel, Sandro, Duffy, Tomas, Bisio, Margarita, Ramirez, Juan Carlos, Duncanson, Fred, Everson, Michael, Daniels, Antonia, Asada, Makoto, Cox, Eugene, Wesche, David, Diderichsen, Paul Matthias, Marques, Alexandre F, Izquierdo, Luis, Sender, Silvia Sanz, Reverter, Joan Carlos, Morales, Manuel, Jimenez, Wladimiro, Torrico, Faustino, Gascon, Joaquim, Ortiz, Lourdes, Alonso-Vega, Cristina, Pinazo, María-Jesús, Schijman, Alejandro, Almeida, Igor C, Alves, Fabiana, Strub-Wourgaft, Nathalie, and Ribeiro, Isabela

Published
2018
Full Text
View/download PDF

19. Identification of Trypanosoma cruzi Discrete Typing Units (DTUs) in Latin-American migrants in Barcelona (Spain)

Author

Abras, Alba, Gállego, Montserrat, Muñoz, Carmen, Juiz, Natalia A, Ramírez, Juan Carlos, Cura, Carolina I, Tebar, Silvia, Fernández-Arévalo, Anna, Pinazo, María-Jesús, de la Torre, Leonardo, Posada, Elizabeth, Navarro, Ferran, Espinal, Paula, Ballart, Cristina, Portús, Montserrat, Gascón, Joaquim, and Schijman, Alejandro G

Published
2017
Full Text
View/download PDF

22. Development and Application of an Assay to Evaluate the Anti-Parasitic Effect of Humoral Responses against Trypanosoma cruzi

Author

Martinez-Peinado, Nieves, primary, Gabaldon-Figueira, Juan Carlos, additional, Martinez-Añon, Ignacio, additional, Rodríguez-Gordo, Cristian, additional, Robleda-Castillo, Raquel, additional, Pinazo, Maria-Jesus, additional, Bigey, Pascal, additional, Gascon, Joaquim, additional, and Alonso-Padilla, Julio, additional

Published
2023
Full Text
View/download PDF

23. A Branched and Double Alpha-Gal-Bearing Synthetic Neoglycoprotein as a Biomarker for Chagas Disease

Author

Montoya, Alba L., primary, Carvajal, Elisa G., additional, Ortega-Rodriguez, Uriel, additional, Estevao, Igor L., additional, Ashmus, Roger A., additional, Jankuru, Sohan R., additional, Portillo, Susana, additional, Ellis, Cameron C., additional, Knight, Colin D., additional, Alonso-Padilla, Julio, additional, Izquierdo, Luis, additional, Pinazo, Maria-Jesus, additional, Gascon, Joaquim, additional, Suarez, Veronica, additional, Watts, Douglas M., additional, Malo, Iliana R., additional, Ramsey, Janine M., additional, Alarcón De Noya, Belkisyolé, additional, Noya, Oscar, additional, Almeida, Igor C., additional, and Michael, Katja, additional

Published
2022
Full Text
View/download PDF

25. A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease

Author

Torrico, Faustino, primary, Gascón, Joaquim, additional, Ortiz, Lourdes, additional, Pinto, Jimy, additional, Rojas, Gimena, additional, Palacios, Alejandro, additional, Barreira, Fabiana, additional, Blum, Bethania, additional, Schijman, Alejandro Gabriel, additional, Vaillant, Michel, additional, Strub-Wourgaft, Nathalie, additional, Pinazo, Maria-Jesus, additional, Bilbe, Graeme, additional, and Ribeiro, Isabela, additional

Published
2022
Full Text
View/download PDF

27. A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease.

Author

Torrico, Faustino, Gascón, Joaquim, Ortiz, Lourdes, Pinto, Jimy, Rojas, Gimena, Palacios, Alejandro, Barreira, Fabiana, Blum, Bethania, Schijman, Alejandro Gabriel, Vaillant, Michel, Strub-Wourgaft, Nathalie, Pinazo, Maria-Jesus, Bilbe, Graeme, and Ribeiro, Isabela

Subjects
ANTIPROTOZOAL agents, DRUG efficacy, CHRONIC diseases, TROPICAL medicine, RANDOMIZED controlled trials, TRYPANOSOMIASIS, BLIND experiment, RESEARCH funding, DESCRIPTIVE statistics, POLYMERASE chain reaction, STATISTICAL sampling, NEGLECTED diseases, EVALUATION, ADULTS
Abstract

Background Chagas disease (CD) has significant global health impact, but safe, effective treatments remain elusive. The nitroimidazole fexinidazole is a potential treatment. Methods This double-blind, randomized, placebo-controlled, dose-finding, proof-of-concept study was conducted in Bolivia. Adults with serologically confirmed chronic indeterminate CD and positive PCR were randomly assigned to 1 of 6 fexinidazole regimens (1200 or 1800 mg/day for 2, 4, or 8 weeks) or placebo. Target recruitment was 20 patients/arm. The primary endpoint was sustained parasitological clearance by serial negative qPCR from end of treatment (EOT) until 6 months follow-up in the intention-to-treat (ITT) population. Follow-up was extended to 12 months. Results Enrollment was interrupted after 4/47 patients presented with transient asymptomatic grade 3 and 4 neutropenia. Treatment of ongoing patients was stopped in all patients administered >2 weeks. A total of 40 patients received treatment with fexinidazole from 3 days to 8 weeks. Delayed-onset neutropenia (n = 8) and increased liver enzymes (n = 8) were found in fexinidazole patients vs none in the placebo arm. In the ITT analysis, sustained parasitological clearance from EOT to 12 months follow-up varied between 66.7% (1200 mg–2 week) and 100.0% (1800 mg–2 week). Rapid, sustained clearance of parasitemia was observed in all treated patients with available data, but not in any patients in the placebo group, at 12 months (P =.0056). Further exploratory exposure-response analysis suggested low dosages of fexinidazole may be safe and effective. Conclusions Further evaluation is needed to establish fexinidazole's minimum effective dosage and risk–benefit relationship. Results suggest potential for effective treatment regimens <10 days. Clinical Trials Registration NCT02498782. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Results and evaluation of the expansion of a model of comprehensive care for Chagas disease within the National Health System: The Bolivian Chagas network

Author

Pinazo, Maria-Jesus, Rojas-Cortez, Mirko, Saravia, Ruth, Garcia-Ruiloba, Wilson, Ramos, Carlos, Pinto Rocha, Jimy-Jose, Ortiz, Lourdes, Castellon, Mario, Mendoza-Claure, Nilce, Lozano, Daniel, Torrico, Faustino, Gascon, Joaquim, Chagas Platform and, and Chagas Healthcare Network working group

Subjects
Bolívia, Bolivia, Antiparasitic Agents, National Health Programs, Health Personnel, Trypanosoma cruzi, Public Health, Environmental and Occupational Health, Primary care, Health Services Accessibility, Chagas' disease, Infectious Diseases, Malaltia de Chagas, Atenció primària, Diagnòstic, Diagnosis, Humans, Chagas Disease, Comprehensive Health Care
Abstract

Background Most people with chronic Chagas disease do not receive specific care and therefore are undiagnosed and do not receive accurate treatment. This manuscript discusses and evaluates a collaborative strategy to improve access to healthcare for patients with Chagas in Bolivia, a country with the highest prevalence of Chagas in the world. Methods With the aim of reinforcing the Chagas National Programme, the Bolivian Chagas Platform was born in 2009. The first stage of the project was to implement a vertical pilot program in order to introduce and consolidate a consensual protocol-based healthcare, working in seven centers (Chagas Platform Centers). From 2015 on the model was extended to 52 primary healthcare centers, through decentralized, horizontal scaling-up. To evaluate the strategy, we have used the WHO ExpandNet program. Results The strategy has significantly increased the number of patients cared for, with 181,397 people at risk of having T. cruzi infection tested and 57,871 (31·9%) new diagnostics performed. In those with treatment criteria, 79·2% completed the treatment. The program has also trained a significant number of health personnel through the specific Chagas guidelines (67% of healthcare workers in the intervention area). Conclusions After being recognized by the Chagas National Programme as a healthcare model aligned with national laws and priorities, the Bolivian platform of Chagas as an innovation, includes attributes that they have made it possible to expand the strategy at the national level and could also be adapted in other countries.

Published
2022

32. Community-based entomological surveillance in three Chagas disease-endemic regions in sub-Andean Bolivia

Author

Rojas-Cortez, Mirko, primary, Pinazo, Maria-Jesus, additional, Gascon, Joaquim, additional, Gamarra, Enzo, additional, Grageda, Rosse Mary, additional, Fernandez, Rene, additional, Rueda, Eduardo, additional, Pinto, Jimy, additional, Anzoleaga, Helmut Magne, additional, Caballero, Yurly Escobar, additional, Urioste, Gloria Sandy, additional, Sanchez, Jareth, additional, Saravia, Ruth, additional, Castellon, Mario, additional, Garcia, Wilson, additional, Daza, Lourdes Ortiz, additional, Mur, Isabel Gonzales, additional, Lozano, Daniel, additional, Carvalho-Costa, Filipe Anibal, additional, Monteiro, Fernando Araújo, additional, and Torrico, Faustino, additional

Published
2021
Full Text
View/download PDF

33. Serological reactivity against T. cruzi-derived antigens: Evaluation of their suitability for the assessment of response to treatment in chronic Chagas disease.

Author

Alonso-Padilla, Julio, primary, López, Manuel Carlos, additional, Esteva, Mónica, additional, Zrein, Maan, additional, Casellas, Aina, additional, Gómez, Inmaculada, additional, Granjon, Elodie, additional, Méndez, Susana, additional, Benítez, Celia, additional, Ruiz, Andres Mariano, additional, Sanz, Sergi, additional, Gascón, Joaquim, additional, Thomas, M Carmen, additional, Pinazo, Maria-Jesus, additional, Abril, Marcelo, additional, de Noya, Belkisyolé Alarcón, additional, Jorge, Tania Araujo, additional, Chatelain, Eric, additional, Grijalva, Mario J., additional, Guhl, Felipe, additional, Hasslocher-Moreno, Alejandro Marcel, additional, Luquetti, Alejandro O., additional, Noya, Oscar, additional, Ramsey, Janine M., additional, Ribeiro, Isabela, additional, Longhi, Silvia A., additional, Schijman, Alejandro G., additional, Sosa-Estani, Sergio, additional, Torrico, Faustino, additional, and Viotti, Rodolfo, additional

Published
2021
Full Text
View/download PDF

35. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial

Author

Torrico, Faustino, primary, Gascón, Joaquim, additional, Barreira, Fabiana, additional, Blum, Bethania, additional, Almeida, Igor C, additional, Alonso-Vega, Cristina, additional, Barboza, Tayná, additional, Bilbe, Graeme, additional, Correia, Erika, additional, Garcia, Wilson, additional, Ortiz, Lourdes, additional, Parrado, Rudy, additional, Ramirez, Juan Carlos, additional, Ribeiro, Isabela, additional, Strub-Wourgaft, Nathalie, additional, Vaillant, Michel, additional, Sosa-Estani, Sergio, additional, Arteaga, Roger, additional, de la Barra, Anabelle, additional, Camacho Borja, Jhonny, additional, Martinez, Ivana, additional, Fernandes, Jayme, additional, Garcia, Lineth, additional, Lozano, Daniel, additional, Palacios, Alejandro, additional, Schijman, Alejandro, additional, Pinazo, Maria Jesus, additional, Pinto, Jimmy, additional, Rojas, Gimena, additional, Estevao, Igor, additional, Ortega-Rodriguez, Uriel, additional, Mendes, Maria Tays, additional, Schuck, Edgar, additional, Hata, Katsura, additional, Maki, Noritsugu, additional, and Asada, Makoto, additional

Published
2021
Full Text
View/download PDF

36. Novel purine chemotypes with activity against Plasmodium 2 falciparum and Trypanosoma cruzi

Author

Martinez-Peinado, Nieves, Lorente Macias, Alvaro, Garcia-Salbuero, Alejandro, Cortes-Serra, Nuria, Fenollar-Collado, Angel, Ros-Lucas, Albert, Gascon, Joaquim, Pinazo, Maria-Jesus, Molina, Ignacio J., Unciti-Broceta, Asier, Díaz-Mochón, Juan J., Villatoro, Maria J. Pineda de las Infantas y, Izquierdo, Luis, and Alonso-Padilla, Julio

Subjects
Plasmodium Falciparum, parasitic diseases, cytotoxity assays, Trypanosome cruzi, purine metabolism, purine derivatives, pyrimidine analogs, phenotypic assays
Abstract

Malaria and Chagas disease, caused by Plasmodium spp. and Trypanosoma cruzi parasites, 25 remain an important global health problem. Available treatments for those diseases present several 26 limitations such as lack of efficacy, toxic side effects and drug resistance. Thus, finding new drugs 27 is urgently needed. The discovery of new drugs may be benefited by considering significant bio-28 logical differences between host and parasites. One of the most striking differences is found in the 29 purine metabolism because most of the parasites are incapable of de novo purine biosynthesis. 30 Herein, we have analyzed the in vitro anti-P. falciparum and anti-T. cruzi activity of a collection of 81 31 purine derivatives and pyrimidine analogs. We firstly used a primary screening at three fixed 32 concentrations (100, 10 and 1 μM) and progressed to dose-response assays those compounds that 33 kept the growth of the parasites < 30% at 100 μM. Then, we performed two different cytotoxicity 34 assays on Vero cells and human HepG2 cells. Finally, compounds specifically active against T. cruzi 35 were tested against intracellular amastigote forms. Purines 33 (IC50 = 19.19 μM) and 76 (IC50 = 18.27 36 μM) were the most potent against P. falciparum. On the other hand, 6D (IC50 = 3.78 μM) and 34 (IC50 37 = 4.24 μM) were identified as hit purines against T. cruzi amastigotes. Moreover, an in silico docking 38 study revealed that P. falciparum and T. cruzi hypoxanthine guanine phosphoribosyltransferase 39 enzymes could be the potential targets of those compounds. Our study identified two novel pu-40 rine-based chemotypes that can be further optimized to generate potent and diversified an-41 ti-parasitic drugs against both parasites.

Published
2021

37. Extracellular Vesicles in Infection: Immunomodulatory Effects and Future Perspectives as Potential Control Tools against Chagas Disease.

Author

Cortes-Serra, Nuria, Gualdron-Lopez, Melisa, Pinazo, Maria-Jesus, Torrecilhas, Ana Claudia, and Fernandez-Becerra, Carmen

Subjects
CHAGAS' disease, EXTRACELLULAR vesicles, TRYPANOSOMA cruzi, NEGLECTED diseases, TRICHOMONIASIS, BURULI ulcer, VACCINE development
Abstract

Chagas disease, caused by the protozoa parasite Trypanosoma cruzi, is a neglected tropical disease and a major public health problem affecting more than 6 million people worldwide. Many challenges remain in the quest to control Chagas disease: the diagnosis presents several limitations and the two available treatments cause several side effects, presenting limited efficacy during the chronic phase of the disease. In addition, there are no preventive vaccines or biomarkers of therapeutic response or disease outcome. Trypomastigote form and T. cruzi-infected cells release extracellular vesicles (EVs), which are involved in cell-to-cell communication and can modulate the host immune response. Importantly, EVs have been described as promising tools for the development of new therapeutic strategies, such as vaccines, and for the discovery of new biomarkers. Here, we review and discuss the role of EVs secreted during T. cruzi infection and their immunomodulatory properties. Finally, we briefly describe their potential for biomarker discovery and future perspectives as vaccine development tools for Chagas Disease. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. Novel Purine Chemotypes with Activity against Plasmodium falciparum and Trypanosoma cruzi

Author

Martinez-Peinado, Nieves, primary, Lorente-Macías, Álvaro, additional, García-Salguero, Alejandro, additional, Cortes-Serra, Nuria, additional, Fenollar-Collado, Ángel, additional, Ros-Lucas, Albert, additional, Gascon, Joaquim, additional, Pinazo, Maria-Jesus, additional, Molina, Ignacio J., additional, Unciti-Broceta, Asier, additional, Díaz-Mochón, Juan J., additional, Pineda de las Infantas y Villatoro, María J., additional, Izquierdo, Luis, additional, and Alonso-Padilla, Julio, additional

Published
2021
Full Text
View/download PDF

39. Additional file 1 of Amaryllidaceae plants: a potential natural resource for the treatment of Chagas disease

Author

Martínez-Peinado, Nieves, Cortes-Serra, Nuria, Tallini, Luciana R., Pinazo, Maria-Jesus, Gascon, Joaquim, Bastida, Jaume, and Alonso-Padilla, Julio

Abstract

Additional file 1: Table S1. Active extracts IC50, TC50 and SI parameters are shown for each extract. IC50 and TC50 R2 statistical indicator is also included in the table. Those extracts that presented specific activity (SI > 20) are highlighted in grey.

Published
2021
Full Text
View/download PDF

40. Additional file 3 of Amaryllidaceae plants: a potential natural resource for the treatment of Chagas disease

Author

Martínez-Peinado, Nieves, Cortes-Serra, Nuria, Tallini, Luciana R., Pinazo, Maria-Jesus, Gascon, Joaquim, Bastida, Jaume, and Alonso-Padilla, Julio

Abstract

Additional file 3: Figure S1. Dose response curves of standard drug BNZ and DTX. (A) Anti-T. cruzi assay (circles), anti-amastigote assay (triangles) and Vero cell toxicity assay (squares) of BNZ. (B) HepG2 cell toxicity assays of BNZ and (C) DTX, respectively.

Published
2021
Full Text
View/download PDF

44. COVID-19: Implications for People with Chagas Disease

Author

Zaidel, Ezequiel José, Forsyth, Colin J., Novick, Gabriel, Marcus, Rachel, Ribeiro, Antonio Luiz P., Pinazo, Maria-Jesus, Morillo, Carlos A., Echeverría, Luis Eduardo, Shikanai-Yasuda, Maria Aparecida, Buekens, Pierre, Perel, Pablo, Meymandi, Sheba K., Ralston, Kate, Pinto, Fausto, Sosa-Estani, Sergio, and Repositório da Universidade de Lisboa

Subjects
Chagas Cardiomyopathy, Chagas disease, lcsh:Diseases of the circulatory (Cardiovascular) system, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Epidemiology, Neglected tropical disease, Review, Comorbidity, 030204 cardiovascular system & hematology, Health Services Accessibility, 03 medical and health sciences, 0302 clinical medicine, COVID-19, Chagas Disease, Neglected Tropical Disease, Risk Factors, Tropical Medicine , Cardiology, Pandemic, Health care, medicine, Humans, 030212 general & internal medicine, Intensive care medicine, Community and Home Care, Health Services Needs and Demand, business.industry, lcsh:Public aspects of medicine, Neglected Diseases, Tropical disease, lcsh:RA1-1270, medicine.disease, Cross-Sectional Studies, lcsh:RC666-701, Etiology, Coinfection, Cardiology and Cardiovascular Medicine, business, Follow-Up Studies, Forecasting
Abstract

© 2020 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/, As the global COVID-19 pandemic advances, it increasingly impacts those vulnerable populations who already bear a heavy burden of neglected tropical disease. Chagas disease (CD), a neglected parasitic infection, is of particular concern because of its potential to cause cardiac, gastrointestinal, and other complications which could increase susceptibility to COVID-19. The over one million people worldwide with chronic Chagas cardiomyopathy require special consideration because of COVID-19's potential impact on the heart, yet the pandemic also affects treatment provision to people with acute or chronic indeterminate CD. In this document, a follow-up to the WHF-IASC Roadmap on CD, we assess the implications of coinfection with SARS-CoV-2 and Trypanosoma cruzi, the etiological agent of CD. Based on the limited evidence available, we provide preliminary guidance for testing, treatment, and management of patients affected by both diseases, while highlighting emerging healthcare access challenges and future research needs., The authors would like to thank Marina Certo, DNDi Platforms Coordination Officer, for invaluable support of the writing group. DNDi is grateful to its donors, public and private, who have provided funding to DNDi since its inception in 2003. A full list of DNDi donors can be found at http://www.dndi.org/donors/donors. MASY is grateful for financial support from FAPESP 2012/50273-0. ALPR is grateful for support from CNPq (310679/2016-8 and 465518/2014-1) and FAPEMIG (PPM-00428-17).

Published
2020

45. Anti-Trypanosoma cruzi Activity of Metabolism Modifier Compounds

Author

Martinez-Peinado, Nieves, primary, Martori, Clara, additional, Cortes-Serra, Nuria, additional, Sherman, Julian, additional, Rodriguez, Ana, additional, Gascon, Joaquim, additional, Alberola, Jordi, additional, Pinazo, Maria-Jesus, additional, Rodriguez-Cortes, Alheli, additional, and Alonso-Padilla, Julio, additional

Published
2021
Full Text
View/download PDF

47. Malaria prophylaxis approach during COVID-19 pandemic

Author

Rodriguez-Valero, Natalia, primary, Vera, Isabel, additional, Torralvo, Montse Roldan, additional, De Alba, Teresa, additional, Ferrer, Elisabeth, additional, Camprubi, Daniel, additional, Almuedo Riera, Alex, additional, Gallego, Ruth Sotil, additional, Muelas, Magdalena, additional, Pinazo, Maria Jesus, additional, and Muñoz, Jose, additional

Published
2020
Full Text
View/download PDF

48. COVID-19: Implications for People with Chagas Disease

Author

Zaidel, Ezequiel, primary, Forsyth, Colin, additional, Novick, Gabriel, additional, Marcus, Rachel, additional, Ribeiro, Antonio Luiz, additional, Pinazo, Maria Jesus, additional, Morillo, Carlos, additional, Echeverria, Luis Eduardo, additional, Shikanai-Yasuda, Maria Aparecida, additional, Buekens, Pierre, additional, Perel, Pablo, additional, Meymandi, Sheba, additional, Ralston, Kate, additional, Pinto, Fausto, additional, and Sosa-Estani, Sergio, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results